Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions
Ulcerative Colitis Chronic ModerateUlcerative Colitis Chronic Severe
Interventions
DRUG

OST-122

Active dose

DRUG

Placebo

Placebo

Trial Locations (16)

17007

Hospital Universitari Doctor Josep Trueta, Girona

41009

Hospital Universitario Virgen Macarena, Seville

Unknown

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

Hospital Universitario Fundación Alcorcón, Alcorcón

Complejo Hospitalario de Navarra, Pamplona

Hospital Álvaro Cunqueiro, Vigo

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Reina Sofía, Córdoba

Hospital San Jorge, Huesca

Hospital Infanta Leonor, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario Central de Asturias, Oviedo

Hospital Clínico Universitario Lozano Blesa, Zaragoza

Hospital Universitario Miguel Servet, Zaragoza

"Medical and Diagnostic Center PE PMC Acinus", Kropyvnytskyi

"Medical Center Ok!Clinic of International Institute of Clinical Research LLC", Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oncostellae S.L

INDUSTRY

NCT04353791 - Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis | Biotech Hunter | Biotech Hunter